SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
Keyword(s):
ABSTRACT Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR) A. baumannii strain. In standard in vitro assays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection.
2016 ◽
Vol 60
(11)
◽
pp. 6892-6895
◽
Keyword(s):
2019 ◽
Vol 68
(7)
◽
pp. 1096-1108
◽
2018 ◽
Vol 51
(1)
◽
pp. 157
2015 ◽
Vol 59
(12)
◽
pp. 7316-7319
◽
2018 ◽
Vol 18
(1)
◽
2018 ◽
Vol 63
(2)
◽
pp. e01489-18
◽
2016 ◽
Vol 49
(6)
◽
pp. 924-933
◽
2012 ◽
Vol 56
(8)
◽
pp. 4140-4145
◽